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Merkel cell carcinoma is a very rare and aggressive neoplasm. Due to its rarity, therapeutic guidelines are not well
established, especially for regionally advanced disease. Articles in English, French, Italian, Portuguese, and Spanish
from the last 20 years were identified in MEDLINE and reviewed. The key word ‘‘Merkel’’ was used for the search,
relevant articles were selected, and their references were examined. The most important articles related to
epidemiology, genesis and treatment were reviewed. The incidence of Merkel cell carcinoma is increasing due to
the advancing age of the population, higher rates of sun exposure and an increasing number of immunocom-
promised individuals. With regard to etiology, the recently described Merkel Cell polyomavirus is thought to play a
role. Either local or regional surgical intervention remains the standard of care, but adjuvant radiotherapy or
radiotherapy as a primary treatment have been discussed as reasonable therapeutic options. An update on this rare
neoplasia is essential because of its increasing incidence and changing treatment options.
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INTRODUCTION
Merkel Cell Carcinoma (MCC) is a very rare and aggressive
neoplasm. Due to its rarity, therapeutic guidelines are not well
established, especially for regionally advanced cases.
METHOD
The MEDLINE database was searched for articles written
in English, French, Italian, Portuguese, and Spanish. The
key word ‘‘Merkel’’ was used as the basis for these searches.
Relevant articles were selected, and their references were
also evaluated.
DISCUSSION
Epidemiology and Etiopathology
Merkel Cell Carcinoma (MCC) is a rare and aggressive
neoplasia that was first described in 1972 by Toker.1 This
tumor likely originates from a cutaneous mechanoreceptor
cell (Merkel cell) located in the basal layer of the epidermis.
In the last decade, reports on Merkel cell carcinoma have
increased significantly, primarily due to the advent of new
and specific immunohistochemical staining methods. This
unusual cutaneous neuroendocrine neoplasia has many
synonyms including ‘‘cutaneous neuroendocrine carci-
noma,’’ ‘‘cutaneous trabecular carcinoma,’’ and ‘‘small cell
primary cutaneous carcinoma’’.1,2 Currently, 950 to 1,300
cases of MCC are diagnosed per year in the United States.
This number appears to be increasing due to the advancing
age of the population, the higher incidence of damaging sun
exposure, and increasing numbers of immunocompromised
individuals.3-7 Feng et al. recently described a polyomavirus
isolated from MCC specimens, which may explain why
MCC is more frequently observed in immunocompromised
patients. These authors studied ten tumors and detected the
virus in eight cases. In six of the eight positive tumors, the
virus was integrated into the tumor genome. In non-MCC
patients, integration was observed in 16% of cases.8
The estimated annual incidence of MCC is 0.23 per
100,000 individuals for Caucasians, whereas the incidence in
those of African descent is 0.01 per 100,000 and appears to
be even lower in Polynesians. Merkel cell carcinoma occurs
predominantly in elderly persons, with a mean of 69 years-
old at diagnosis.9-11 Males are affected more commonly than
females (61% male vs. 39% female).12 Other tumors, such as
squamous cell carcinoma and chronic lymphocytic leuke-
mia, are also common in this population.11
Angiogenesis has been described by many authors in this
rare tumor. Gaudin and Rosai described a vascular
distribution pattern common to Merkel and other neural
and neuroendocrine neoplasms characterized by tufts of
vessels, similar to a glomeruloid pattern, or long cords of
vessels.13 They proposed that this characteristic pattern may
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be caused by angiogenic factors produced by these tumors.
Furthermore, Kukko et al. analyzed the expression of
vascular endothelial growth factor receptor-2 (VEGFR-2) in
Merkel tumors and found a strong positive correlation
between the presence of VEGFR-2, tumor size and meta-
static potential.14 In that study, the authors suggested that
antiangiogenic therapy could help control the tumor, but
this was not analyzed experimentally. It has been shown
in experimental models of MCC that inhibitors of the
mTor pathways result in reduced VEGF production and
angiogenesis.15
Recently, an interesting study was conducted by Vazmitel
et al.16 involving 92 cases of MCC. They found prominent
vascular alterations in 18 cases (20%). Pericyte hyperplasia
was observed in ten cases (11%) among others six different
patterns. In this interesting study, the presence of HHV-8
was analyzed because this virus is known to stimulate
angiogenesis. However, HHV-8 was not detected with the
polymerase chain reaction.
Studies have been conducted on many tumors, including
MCC, involvingmTor receptors and the AKT/PI3C pathway.
mTor (Mammalian Target of Rapamycin) is a protein kinase
and a member of the PIKK family that controls cell growth.
mTor is regulated by many factors, such as growth factors,
hormones (insulin), and the PI3K/Akt pathway. This path-
way is initiated by growth factor receptors, such as IGFR
(Insulin-like Growth Factor Receptor), PDGFR (Platelet-
Derived Growth Factor Receptor), EGFR (Epidermal
Growth Factor Receptor), and the HER family.17,18 In this
particular pathway, inactivation of PTEN, which commonly
occurs in human tumors, is antagonistic to PI3K and results
in increases in PIP3. PI3K activation and accumulation of
PIP3 causes translocation of Akt to the plasma membrane,
where Akt is activated. These steps initiate anti-apoptotic
pathways and stimulate the cell cycle via a series of factors,
including mTOR. Akt/mTOR can regulate suppression of
p53, and Akt can activate mdm2 and promote p53 degrada-
tion. In models of MCC, inhibition of Ras causes apoptosis
with p53 degradation, so it is very likely that this pathway is
involved in MCC.19,20
It is well accepted that Merkel carcinoma commonly
occurs in immunocompromised patients, and in this
population, changing the immunosuppression regimen
from calcineurin inhibitors (azathioprine and cyclosporine)
to serolimus results in better cure rates and regression of
tumors.21 Serolimus (rapamycin) acts both via the inhibition
of the mTOR pathway and by diminishing angiogenesis.22 It
has been tested prospectively after transplants, and there
was a significant reduction of skin and non-skin cancers.23
Furthermore, serolimus has been tested for MCC.19
In an experimental model of MCC, the use of imatinib has
been tested. It has been suggested that an autocrine and
paracrine activation of KIT receptors in MCC cell lines
occurs via stem cell factor (SCF) and induces the MAPK
pathway and AKT activation. Although MCC cells display
some response to imatinib, a high dose is necessary to
obtain cell death. However, relapse has been observed and
is most likely due to direct activation of MEK1 and AKT,
which induces further proliferation and anti-apoptosis
effects, respectively. This pathway is promising as a novel
therapeutic option for this tumor.24
Diagnosis
MCC occurs predominantly in the head and neck (41 to
50%), followed by the extremities (32 to 38%) and trunk (12
to 14%). Typically, this neoplasm presents as a rapidly
growing, dome-shaped red or bluish nodule.10,12,25 In
addition, the tumor may sometimes have a plaque-like
appearance with small satellite lesions.3
Diagnosis is usually established only after biopsy. Similar
to other neuroendocrine tumors, small round to ovoid cells
with hyperchromatic nuclei and frequent mitosis or
apoptosis are commonly observed. The architecture is often
variable and includes trabecular, nodular and diffuse
patterns. Sometimes, it is difficult to differentiate MCC
from other small cell tumors, and in these cases, immuno-
histochemical staining and/or electron microscopy must be
used. MCC stains positively for neuron-specific enolase,
synaptophysin, chromogranin, cytokeratin 20 (in a char-
acteristic dot-like pattern) and CAM 5.2 and is negative
for S100, desmin and common leukocyte antigens.10
Cytokeratin-20 expression is detected in 89 to 100% of
MCC cases as well as in 30% of small-cell lung tumors.26
Stage Classification
Yiengpruksawan27 proposed a stage classification forMCC
as follows: stage I would be restricted to the skin, stage II
would include nodal metastasis, and stage III would be
Table 1 - TNM Classification.
Tumor (T)
T1 #2 cm tumor size
T2 .2 cm but no more than 5 cm
T3 .5 cm
T4 invasion of bone, muscle, fascia or cartilage
Nodal (N)
cN0 node negative by clinical exam (clinical or imaging exam)
pN0 node negative by pathologic exam
N1 metastasis in regional node
N1a micrometastasis (sentinel node or elective lymphadenectomy)
N1b macrometastasis (clinically detectable, confirmed by surgery or fine-needle aspiration)
N2 in-transit metastasis
Metastasis (M)
M0 no distant metastasis
M1 metastasis beyond regional lymph nodes
M1a metastasis to skin, subcutaneous tissues or distant lymph nodes
M1b metastasis to lung
M1c metastasis to all other visceral sites
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characterized by distant metastasis. Later, stage I disease was
classified as IA (#2 cm) or IB (.2 cm) based on publications
by Yiengpruksawan and Allen.25,27,28 However, that study
was not able to show any statistical differences in the
prognosis between tumor size groups. In a study of 251
patients, Allen et al. showed that the proposed stage system
with the division of IA and IB resulted in a different
prognosis; thus, they used a four-stage system defined as
follows: Stage I T (tumor size) ,2 cm, Stage II T $2 cm with
no evidence of regional or distant disease, Stage III with
positive lymph nodes in the drainage basin, and Stage IV
with distant metastasis. After a forty-month average follow-
up, the survival rates were 81% for Stage I, 67% for Stage II,
52% for Stage III, and 11% for Stage IV.29 Pitale et al. did not
observe any influence of the tumor size on the prognosis of
306 patients, but their meta-analysis was a summary of the
literature and did not represent data from a single institu-
tion.30 Lemos et al. evaluated 2,856 patients and were able to
analyze the impact of tumor size with 1-cm increments. They
found that the most important difference was between
#2 cm and more than 2 cm (five-year survival rate of 66%
vs. 51%, respectively; p,0.0001). Interestingly, tumors that
are,1 cm are associated with only minimal improvement in
survival when compared with those that are 1 to 2 cm in
diameter (69% vs. 61%, respectively).12
Nodal disease is an important negative prognostic factor
for this type of tumor. Clinical versus pathological staging
seems to be important in prognosis and treatment; patients
with a clinically enlarged node had a worse prognosis than
those whose nodes were evaluated histopathologically by
sentinel lymph node biopsy, fine needle aspiration or
elective lymphadenectomy.12 Even in the tumor (T) cate-
gory, the authors categorized the tumors as pathologically
negative or clinically negative nodes, with different prog-
noses (Tables 1 and 2). It is noteworthy that approximately
50 to 70% of all patients will develop lymph node
metastases, and of these patients, 33 to 70% will develop
distant disease.1,2,30-35 The most frequent sites of metastasis
are liver (13%), bone (10-15%), lung (10-23%), brain (18%),
distant skin (9-30%) and distant lymph nodes (9%).29,36-38
In the largest patient cohort of patients from the American
National Cancer Database, Lemos et al. evaluated the
mortality of each clinical presentation and adjusted for
age. For the overall population, the 5-year survival was 54%;
for those with local, nodal and distant disease at presenta-
tion, these values were 64, 39, and 18%, respectively.12
The Seventh Edition of AJCC39 integrates Lemos et al.’s
findings, as summarized in Table 2 (excluded Tx and T0).
It was possible, with a greater cohort of patients, to show
that in the nodal-negative group clinically evaluated,
relative survival was worse when compared to pathologyi-
cal proof, such as sentinel, fine-needle or elective lymph
node biopsy (HR 1.80, 95% confidence interval 1.4-2.4,
p,0.0001). For the positive nodal group, the survival was
worse when a node was clinically detected (HR 1.48, 95%
confidence interval 1.1-1.9, p= 0.004).12
Treatment
Due to its rare incidence, there is currently a lack of
standard therapeutic procedures ascribed for the treatment
of MCC, especially when the disease is locally advanced.
Surgical excision and radiotherapy remain the mainstays of
therapy in the initial stages.2,10,25,27,31,32
Primary Lesion
Following a confirmatory biopsy of a suspected lesion
that confirms the diagnosis, surgery is the usual treatment
choice.2,10,27,31,32,36 Depending on the physician’s and
patient’s preference, a wide local excision made deep into
the muscle fascia or Mohs micrographic surgery can be
performed. Both are successful in achieving tumor-free
margins and an acceptable level of disease-free survival. Of
note, at our institution, the wide margin resection was
preferred. If Mohs micrographic surgery (MMC) is per-
formed, adjuvant radiotherapy seems to be essential. In
support of this, Boyer et al. conducted a study among
patients who underwent Mohs surgery. Twenty patients
had radiotherapy as adjuvant treatment, and 25 did not
receive any adjuvant radiotherapy. In the adjuvant radio-
therapy group, there was no recurrence, but in the Mohs
surgery-only group, recurrence was detected in four cases.
Given the small study numbers, this difference was not
statistically significant.40 Since adjuvant radiotherapy is
typically performed regardless of a tumor’s margins, it is
not reasonable to compare wide local excision and MMC.
Wide local excision for MCC is often performed as it is
performed for melanoma, with 2 cm margins, if feasible.
Unfortunately, there are no prospective studies on the ideal
margin. Allen et al., in a study of 251 patients from a single
institution, found that obtaining a surgical margin of more
than 1 cm was not associated with decreased local recur-
rence (,1 cm 9% vs. $1 cm 10%, p=0.8). Local recurrence
occurred in 18% of patients with positive margins; if the
margins were negative, recurrence occurred in 8%, and this
difference was not statistically significant (p= 0.31). In
addition, in their study, the use of radiotherapy as opposed
to surgery did not decrease the local recurrence rate
(radiotherapy 10% vs. no radiotherapy 8%, p= 0.76).
Unfortunately, this was not a randomized study, so patients
with tumors $2 cm received additional adjuvant radio-
therapy (,2 cm 10% vs. $2 cm 23%, p= 0.02). It is also
worth noting that radiotherapy was given only to 12% of
patients, who generally represented the most severe cases;
this could have influenced the outcome in patients with
positive margins who received adjuvant treatment.29
Jabbour et al.41 reinforced previous evidence that, if
adjuvant radiotherapy is associated, the margin does not
interfere with recurrence or survival. Thus, those authors
emphasized the benefit of adjuvant radiotherapy adminis-
tered either locally or regionally.
There are some authors who advocate the use of adjuvant
radiotherapy based on histological features, such as thickness
Table 2 - Staging System.
Stage
Five-year
Survival (%)*
0 Tis N0 M0
IA T1 pN0 M0 79
IB T1 cN0 M0 60
IIA T2/T3 pN0 M0 58
IIB T2/T3 cN0 M0 49
IIC T4 N0 M0 47
IIIA Any T N1a M0 45
IIIB Any T N1b/N2 M0 30
IV Any T Any N M1 18
* (Lemos).
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and angiolymphatic invasion.42 Comparison is very difficult
because each study’s design and characteristics are different;
some compare positive margins, some treat exclusively with
radiotherapy, and some add the evaluation of the draining
lymph node basin. Various protocols reported in reviews are
applied to a large number of patients. Table 3 is an effort to
compile these trends.
In a study of 17 patients, Warner et al. did not observe a
significant impact of a positive sentinel node on the prediction
of regional recurrence. However, they did find that radio-
therapy had an impact on local and regional control.43
Adjuvant radiotherapy is often suggested for large
tumors and for cases in which regional disease is pre-
sent.30,32,33,35,36,44,45 In a meta-analysis by Lewis et al.46 who
compared surgery alone to surgery plus adjuvant radiation,
the authors showed a reduction in local and regional
recurrence in the combined therapy group. That study
encompassed 1,254 patients, and if local radiotherapy was
performed, a decrease in local (88 vs. 61%, respectively;
p,0.001) and regional (77 vs. 44%, respectively; p,0.001)
recurrence was observed, as was an increase in survival (HR
0.63, p= 0.02). It is very important to note that the group
with primary tumors #2 cm benefitted the most from
radiotherapy. Gillenwater et al. found a statistically sig-
nificant difference in local recurrence in the head and neck
region with radiotherapy (12% with vs. 44% without;
p,0.01) and regional therapy (27 vs. 85%; p,0.01) but did
not find a difference in overall survival.47 In a retrospective
study, Meeuwissen et al. showed that all 38 patients treated
with surgery alone relapsed, whereas only 10 in 34 patients
treated with surgery plus radiotherapy relapsed.48 In that
study, the patients treated with surgery plus radiotherapy
were treated at a referred radiotherapy facility, therefore
attending mostly the recurrences. It was not clear whether
the surgeons who referred patients had the skills to treat the
disease.3
A primary lesion that is not resectable can be treated with
radiotherapy as an isolated treatment. The usual dose is 45-
70 Gy.49 Mortier et al. treated nine cases of primary lesions
that could not be treated surgically. After a median follow-
up of three years, there was no recurrence.50 In a larger
series of 43 patients, Veness et al. treated patients who were
non-operable because of clinical or local reasons; 77% of
patients had nodal metastasis. In this particularly bad
prognosis group, they had only 60% relapse, which
commonly occurred out-of-field. The in-field control was
75%. The overall survival after two and five years was 58
and 37%, respectively.51
The Peter MacCallum Cancer Centre in Australia col-
lected robust data on 176 patients. In that cohort, 94% of
patients received radiotherapy. In the multivariate analysis,
the dose of radiotherapy was significantly different for
locoregional control. They divided their cohort into three
groups: a) no radiotherapy, b) radiotherapy ,45 Gy and c)
radiotherapy $45 Gy; Comparing the control achieved in
the groups, respectively was 51 vs. 71 vs. 80 months
p= 0.044 and overall survival, p= 0.005). However, only 11
patients received no radiotherapy.52
Regional Treatment
In the absence of clinically positive lymph nodes, most
centers will perform a sentinel lymph node biopsy (SLNB)
to obtain accurate nodal staging. As stated previously, this
is an important prognostic factor.3,6,43,53 The SLNB techni-
que is conducted in the same manner as in melanoma
patients. Immunohistochemistry for CK-20 is a valuable tool
in identifying micrometastases. Allen et al. found 23%
positivity of lymph nodes in patients who underwent
pathologic staging of a clinically negative nodal basin (17
patients underwent elective lymph node dissection and 54
had sentinel lymph node biopsy). Paradoxically, if the
primary lesion was less than 2 cm, the rate of positive nodes
was 24%, and if the tumor was $2 cm, the rate of positive
nodes was 20% (p= 0.71).29 Gupta et al. reviewed 122
patients with MCC who underwent SLNB and observed
that 60% of those patients with a positive sentinel node
recurred in three years (compared to a recurrence rate of
20% in those with negative SLNB).6 Warner et al. analyzed
22 papers involving the use of SLNB for MCC and found
that among 241 patients, 31% had metastases. This group
experienced recurrence in 19% of cases. In the negative
sentinel node group, the recurrence was 7.5%.42 A positive
node, either clinically or pathologically detected, requires
the complete removal of all drainage basin lymph nodes.
Patients who underwent a lymphadenectomy had longer
disease-free survival (28.5 vs. 11.8 months, p= 0.04).41
Follow-up in small groups of patients reinforces this
observation.36,38,53,54 Mehrany et al. performed a meta-
analysis and showed that 15 of 20 patients with positive
sentinel lymph nodes subsequently underwent a lympha-
denectomy and had no regional recurrence after nine
months. In contrast, three of four patients with positive
nodes who did not subsequently undergo lymphadenect-
omy had regional recurrences, with one patient absent from
follow-up.53 Gupta et al. showed that a sentinel lymph node
biopsy is not only important as a prognostic procedure but
can also guide therapy. Data from Lemos et al. have shown
that there is also a survival benefit in performing SLNB, as
already shown in the stage chapter.12
There are some questions about false-negative sentinel
nodes in MCC because compared to melanoma patients, the
mean age is older, and there is a higher incidence in the
Table 3 - Radiotherapy: protocols and results.
Author
Number of
patients
Control primary without
resection % (no)
Control with adjuvant rdt primary (no)/vs. no
radiotherapy Reference
Allen 251 90%(32)/92% (29)
Warner 9 100%(9)/(0) (43)
Boyle 41 36%(30) 91%(11) (33)
Gillenwater ## 66 44%(26)12%/(34) (47)
Mortier 26 100%(9) 93%(27)/0 (50)
Veness 43 75%(43) (51)
## Radiotherapy to primary and lymph node basin - head & neck.
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head and neck region. In both situations, higher numbers of
false-negatives have been obtained during the sentinel node
biopsy evaluation. MCC more frequently invades deep into
the tissues, such as deep dermis and subcutaneous layers,
affecting different sentinel nodes than those of the mela-
noma patients.42 However, data from AJCC 201039 have
shown that the value of the procedure is easily demon-
strated. Patients with positive sentinel lymph nodes who
received adjuvant therapy localized to the nodal positive
basin (surgery, radio-, or chemotherapy) had 50% disease-
free survival at three years, but this was decreased to 0% if
adjuvant therapy was not administered.6 As adjuvant
therapy, a dose of 40 to 50 Gy is administered in 2-Gy
daily fractions to the primary or regional basin.34,41,43
A major discussion in the literature refers to management
after a positive node is detected: is it better to perform a
complete node dissection, radiotherapy only, or both?42 The
answer remains unclear. Lymphadenectomy associated
with radiotherapy in axillary and inguinal regions can lead
to substantial lymphedema. In older patients with micro-
metastases, isolated radiotherapy seems to be a good option.
For good performance status, in patients with larger tumors,
macrometastases, or extra-nodal invasion, combined ther-
apy is a reasonable option. For patients with less-than-
optimal margins, especially in the head-neck region where
adjuvant radiotherapy is planned, it is reasonable to excise
lymph nodes close to the positive node basin (if micro-
metastasis has minimal disease) without performing a
complete lymph node dissection. Extrapolating from studies
of the primary lesion, there are enough data to support that
radiotherapy only applied to the positive sentinel node
basin can be a reasonable option,50,51 but the data for
positive sentinel nodes remain limited. Bichakjian et al.
suggested that with the limited available data, radical
lymphadenectomy should be considered the first-line
treatment for sentinel node positive patients. In cases where
surgery is a high-risk procedure for the patient, radio-
therapy without surgery should be considered.36
If an enlarged regional node is present, lymphadenectomy
and adjuvant radiotherapy are often performed.30,32,33,35,41,44,45
As previously mentioned, in the head and neck region,
Gillenwater et al. found that local and regional recurrence
differed significantlywhen patients received radiotherapy, but
they did not find differences in overall survival.47 Patients
receiving radiotherapy had a regional recurrence rate of 27 vs.
85% compared to those who did not. Disease-free survival
increased from eight to twenty-four months if any radio-
therapy was applied.41 In summary, it seems that adjuvant
radiotherapy is beneficial both locally and regionally.
Distant disease occurs in 36% of patients, regardless of the
adjuvant therapy applied.47 In addition, adjuvant che-
motherapy failed to provide any benefit. Garneski et al.
showed that the chemotherapeutic regimen is toxic, and the
target population is elderly, leading to a treatment-related
death rate of approximately 16% in patients older than 65
years. Morbidity is also high in these cases, and the
chemotherapeutic regimen is adapted from that used for
small-cell lung carcinoma. Without evidence of improved
outcomes, it does not seem reasonable to take on the risk of
such a toxic treatment.29,41,55,56
Distant metastasis
Chemotherapy plays a role in the treatment of distant
metastatic disease. The preferred therapeutic regimen
consists of platinum-based components, such as cisplatin
or carboplatin, plus etoposide or doxorubicin. Response
rates of up to 40% were observed in some studies; however,
those who responded did so only for a short time.33,35,44
In recurrent disease, the choice of treatment becomes a
matter of debate. Many investigators defend radiotherapy as
an important part of the treatment for such patients,27,31,45,57,58
whereas others believe that chemotherapy should play a role
in recurrent disease. However, the results obtained with this
therapy have been disappointing.58,59
Treatment of in-transit metastasis
In-transit disease is a common phenomenon in cutaneous
melanoma, as well as in MCC patients.46,60 For selected
patients with in-transit disease or for whom limb amputa-
tion would be indicated, local control of the tumor and limb
preservation have been achieved with the increased use of
hyperthermic isolated limb perfusion with melphalan.60-64
Alternative treatment options, such as radiotherapy and
chemotherapy, have been reported. For extensive but
localized lesions, radiotherapy can be a good option.
Mortier et al. treated nine cases of primary lesions that
were not eligible for surgical treatment. After a median
follow-up of three years, there was no recurrence.49
Selected cases with in-transit metastasis may be success-
fully treated with isolated perfusion of chemotherapeutic
agents as an alternative to radical surgery.
We recently published a review of the literature on
hyperthermic isolated limb perfusion in MCC, which
covered a series of nine cases, including one case in which
we performed the operation. Five patients were treated with
melphalan alone, and four were treated with melphalan and
TNF-a. All patients treated with melphalan alone had a
complete response, whereas in the melphalan and TNF-a
treatment groups there were two complete responses, one
partial response, and one patient with no response.63
CONCLUSION
The incidence of MCC is increasing due to the advancing
age of the population, a higher incidence of damaging sun
exposure, and an increase in the number of immunocom-
promised individuals. Regarding its etiology of MCC, the
recently described Merkel cell polyomavirus must be
considered. While local or regional surgical treatment
remains the standard of care, adjuvant radiotherapy or
radiotherapy alone have been shown to be reasonable
therapeutic options.
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